Discussion
The first participant has been dosed in Vertero Therapeutics’ Phase 1b clinical trial testing VT-5006, an investigational, gut-directed oral small molecule being developed for Parkinson’s disease. The Phase 1b clinical trial (NCT07310264) is still recruiting adults ages 40-80 with early- or moderate-stage…
